Abstract:Objective: This article investigated the clinical characteristics and distribution of drug resistance mutation sites in HBV RT region of hepatitis B infected patients. Methods: Retrospective analysis was made on 1 948 patients with HBV infection, who had been tested for NAs resistance mutation and had a medical history of NAs in the Laboratory Department of the Fifth Medical Center of the PLA General Hospital from January 2020 to December 2021. Basic clinical information and drug resistance related mutation information were recorded. Meanwhile, the serological index data of hepatitis B were collected. Drug resistance gene mutant group and non-mutated group were grouped according to whether the drug resistance genes had a mutation in HBV RT region, and the clinical characteristics and genotype distribution of the two groups were statistically analyzed. The pattern of drug resistance gene mutation, number of mutation sites, drug resistance type and mutation of NAs resistance-related sites were analyzed in 917 patients with drug resistance gene mutation in HBV RT region. χ2 Inspection was used for counting data. Meanwhile, two independent samples t-test and Wilcoxon rank sum test were used for measurement data. Results: Among the 1 948 patients with chronic HBV infection, 917 patients had drug resistance gene mutation in RT region (47.07%). The proportion of patients with acute hepatitis B and CHB in HBV RT resistance gene mutant group was lower than that in the non-mutated group, while the proportion of patients with HBV-related cirrhosis was higher than that in the non-mutated group, these differences were statistically significant. Compared with the non-mutated group in HBV RT region, the age, the positive rates of HBeAg and HBV DNA, and HBV DNA load of these patients were increased in drug resistance gene mutant group, these differences were statistically significant. Genotypes of patients in both groups were dominated by C, followed by B and D. The proportion of patients with genotype C in HBV RT drug resistance gene mutant group was higher than that of non-mutated group, the difference was statistically significant. There were 53 gene mutation patterns in 917 patients with drug resistance gene mutation in HBV RT region, and the main pattern was rtL180M+rtM204V+rtS202G (9.70%). The mutation sites were dominated by 3 (20.74%). There were 5 types of drug resistance, LAM+Ldt (21.25%) was the most. Among the 18 sites that were clearly associated with LAM, ADV, ETV and Ldt resistance in the HBV RT region, 14 sites were mutated, and the most common mutation sites were rtL180M, rtM204V, rtM204 and rtS202G. what's more, the proportion of patients with NAs drug resistance was LAM>Ldt>ETV>ADV. Conclusion: In order to prevent adverse consequences of this study such as disease recurrence or disease progression caused by HBV drug resistance, HBV infected patients, who have long-term use of NAs antiviral therapy, should monitor the level of HBV DNA and drug resistance genes in HBV RT region in order to optimize the treatment plan in time or guide individualized treatment.

Genetic mutation analysis of HBV covalently closed circular DNA in peripheral blood mononuclear cells from chronic hepatitis B patients with nucleos(t)ide analog-resistant mutations in serum virions

[Sequence Detection of HBV-DNA P and C Region in HIV/HBV Superinfection Subjects with Drug Resistance to HAART].

The Central Nervous System is a Potential Reservoir and Possible Origin of Drug Resistance in Hepatitis B Infection

Profile of Hbv Antiviral Resistance Mutations with Distinct Evolutionary Pathways Against Nucleoside/Nucleotide Analogue Treatment among Chinese Chronic Hepatitis B Patients

Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection

Nucleotide analogue-resistant mutations in hepatitis B viral genomes found in hepatitis B patients.

[Analysis of characteristics of drug resistance gene mutation in HBV RT region of hepatitis B infected patients]

Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.

Discrepancy of Potential Antiviral Resistance Mutation Profiles Within the HBV Reverse Transcriptase Between Nucleos(t)ide Analogue‐untreated and ‐treated Patients with Chronic Hepatitis B in a Hospital in China

Pre-Existing Mutations in Reverse Transcriptase of Hepatitis B Virus in Treatment-Naive Chinese Patients with Chronic Hepatitis B

Drug resistance, genotype, and serotype of hepatitis B virus in nucleos(t)ide analogue naive patients with chronic hepatitis B

Nucleos(t)ide analogues altered quasispecies composition of hepatitis B virus (HBV)-resistant mutations in serum HBV DNA and serum HBV RNA

Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C

Drug resistance mutations related to nucleos(t)ide analogues in Chinese patients with chronic HBV infection: an analysis of 153 cases

Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients.

Analysis of Rtv191i/sw182* Mutation in Chronic Hepatitis B Patients Treated with Nucleos/tide Analogues

Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients.

Impacts of HBV Rth55r Polymerase Substitution on Viral Replication and Rtm204i/v Resistance to Nucleoside/nucleotide Antiviral Drugs.

Natural resistance mutations to direct-acting antiviral agents in interferon/ribavirin treatment-experienced and treatment-naive patients with chronic hepatitis C in Beijing, China

Molecular cloning and phenotypic analysis of drug-resistance mutants with relevant S-region variants of HBV for a patient during 189-month anti-HBV treatment.

Mutation Patterns in the RT Region of Hepatitis B Virus P Gene in Patients Treated with Nucleoside/nucleotide Analogs